A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254
- Citation:
- Leuk Lymphoma vol 52 (4) 587-596
- Year:
- 2011
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10 CA047577, U10 CA032291, CA04457, CA11789, CA47577, CA32291, CA41287, U10 CA035279, CA03927, U10 CA031946, U10 CA033601, CA59518, CA60138, CA26806, U10 CA059518, CA35279, CA12046, U10 CA077440, CA77440, U10 CA041287, U10 CA047559, CA04326, CA21060, CA47559, CA47642, CA37135, U10 CA047642, CA31983, U10 CA003927, CA07968
- Corr. Author:
- Authors:
- Richard R. Furman Michael L. Grossbard Jeffrey L. Johnson Andrew L. Pecora Peter A. Cassileth Sin-Ho Jung Bruce A. Peterson Lee M. Nadler Arnold Freedman Ruthee-Lu Bayer Nancy L. Bartlett David D. Hurd Bruce D. Cheson
- Networks:
- Study
- CALGB-9254
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Lymphoma, anti-B4-blocked ricin, autologous transplant, adjuvant therapy